Stockscreener 앱 받기
3.18
2.15%
-0.07
시간 외 거래:
3.09
-0.09
-2.83%
전일 마감가:
$3.25
열려 있는:
$3.19
하루 거래량:
40,725
Relative Volume:
0.56
시가총액:
$13.48M
수익:
-
순이익/손실:
$-21.79M
주가수익비율:
-0.5142
EPS:
-6.1838
순현금흐름:
$-23.12M
1주 성능:
-1.55%
1개월 성능:
-6.74%
6개월 성능:
-38.85%
1년 성능:
+724.47%
1일 변동 폭
$3.055
$3.23
1주일 범위
$3.055
$3.45
52주 변동 폭
$0.23
$10.19
Cellectar Biosciences Inc Stock (CLRB) Company Profile
명칭
Cellectar Biosciences Inc
전화
(608) 441-8120
주소
100 CAMPUS DRIVE, FLORHAM PARK, NJ
Compare CLRB vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CLRB
Cellectar Biosciences Inc
|
3.18 | 13.78M | 0 | -21.79M | -23.12M | -6.1838 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cellectar Biosciences Inc Stock (CLRB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-10 | 업그레이드 | Maxim Group | Hold → Buy |
| 2024-12-05 | 재개 | Ladenburg Thalmann | Buy |
| 2020-07-01 | 개시 | Oppenheimer | Outperform |
| 2020-01-21 | 재개 | ROTH Capital | Buy |
| 2019-09-13 | 개시 | ROTH Capital | Buy |
| 2016-12-21 | 개시 | Ladenburg Thalmann | Buy |
모두보기
Cellectar Biosciences Inc 주식(CLRB)의 최신 뉴스
Trading Recap: Can Cellectar Biosciences Inc weather a recessionWeekly Investment Report & Safe Capital Investment Plans - baoquankhu1.vn
Risk Report: Does Cellectar Biosciences Inc have a sustainable dividendTake Profit & Daily Stock Trend Watchlist - baoquankhu1.vn
Rate Cut: Can Cellectar Biosciences Inc weather a recessionMarket Growth Report & Short-Term Trading Alerts - baoquankhu1.vn
Cellectar Biosciences (NASDAQ:CLRB) Rating Increased to Buy at Maxim Group - Defense World
CLRB: Maxim Group Upgrades Cellectar Biosciences to Buy with $10 Target | CLRB Stock News - GuruFocus
Ideas Watch: Can Cellectar Biosciences Inc weather a recessionPortfolio Profit Report & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Cellectar Biosciences Stock Drops 17% On $5.8M Fundraise: Retail Awaits An ‘Impending’ Rally - MSN
Cellectar Biosciences Charts Risky Path to Approvals - TipRanks
Quarterly Trades: Does Cellectar Biosciences Inc have a sustainable dividendJuly 2025 Macro Moves & Long-Term Growth Plans - baoquankhu1.vn
Can Cellectar Biosciences Inc weather a recessionWeekly Trading Summary & Safe Capital Growth Plans - baoquankhu1.vn
Should you sell your Cellectar Biosciences stock? - Cantech Letter
Death Cross: Is Cellectar Biosciences Inc vulnerable to short sellersMarket Rally & Capital Efficiency Focused Ideas - baoquankhu1.vn
CG Oncology Soars 102% in a Year, but One Investor Just Disclosed a $58.5 Million Sale - AOL.com
Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q4 2025 Earnings Call Transcript - Insider Monkey
Cellectar (CLRB) Marks Significant Achievements in 2025 - GuruFocus
Cellectar Biosciences, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Earnings call transcript: Cellectar Biosciences Q4 2025 reveals strategic cost control - Investing.com
Cellectar (CLRB) Q4 2025 Earnings Call Transcript - The Globe and Mail
CLRB: Advanced late-stage pipeline, improved financials, and set up for major regulatory milestones in 2026 - TradingView
Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates - Investing News Network
CLRB: Advanced regulatory progress, reduced losses, and extended cash runway position for key 2026 milestones - TradingView
Cellectar Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Earnings Summary: Cellectar Biosciences (CLRB) FY25 net loss narrows - AlphaStreet News
CLRB: Net loss narrowed to $21.8M in 2025, but new funding is needed beyond Q3 2026 - TradingView
CLRB: Net loss narrowed as pipeline advanced toward key regulatory and clinical milestones - TradingView
Cellectar Biosciences 2025 10-K — Net loss $8.35 EPS; no revenue reported - TradingView
Cellectar (NASDAQ: CLRB) halves 2025 loss while pushing key cancer drugs - Stock Titan
Iopofosine progress at Cellectar (NASDAQ: CLRB) with pivotal WM data and FDA path - Stock Titan
Cellectar Biosciences, Inc. Advances Iopofosine I-131 Submission for Waldenström Macroglobulinemia and Initiates Phase 1b Study of CLR 125 in Triple Negative Breast Cancer - Quiver Quantitative
Insights into Cellectar Biosciences's Upcoming Earnings - Benzinga
Cellectar Biosciences Inc expected to post a loss of $2.02 a shareEarnings Preview - TradingView
Cellectar Biosciences (CLRB) to Release Earnings on Wednesday - Defense World
Rate Cut: Is Cellectar Biosciences Inc currently under institutional pressureJuly 2025 PreEarnings & AI Forecast Swing Trade Picks - baoquankhu1.vn
CLRB SEC FilingsCellectar Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Analyst Upgrade: Will Cellectar Biosciences Inc benefit from rising consumer demandMarket Sentiment Summary & Capital Protection Trade Alerts - baoquankhu1.vn
CLRB Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Nasdaq Moves: How cyclical is Cellectar Biosciences Incs revenue streamMarket Performance Recap & High Accuracy Trade Alerts - baoquankhu1.vn
Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Wednesday, March 4, 2026 - Investing News Network
CLRB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Cancer-drug developer Cellectar sets March 4 call on 2025 results - Stock Titan
Bull Bear: What drives Cellectar Biosciences Inc.’s stock priceQuarterly Profit Review & AI Forecasted Entry and Exit Points - mfd.ru
Gap Down: What are Cellectar Biosciences Incs growth leversJuly 2025 Action & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Biotech Exit: $26 Million Arcellx Sale Follows Tepid Stock Performance and Kelonia Competition - AOL.com
Cogent Biosciences Stock Up 346% as Fund Builds $29 Million Stake After November Phase 3 Breakthrough - AOL.com
Cellectar Biosciences Expands Global Intellectual Property Estate - Investing News Network
Cellectar Biosciences Expands Global Intellectual Property Portfolio Ahead of Iopofosine I 131 Marketing Approval for Waldenström Macroglobulinemia - Quiver Quantitative
New patents back Cellectar bid for EMA OK on Waldenström drug - Stock Titan
Will Cellectar Biosciences Inc. benefit from rising consumer demandCEO Change & Comprehensive Market Scan Insights - mfd.ru
Analysis Recap: Whats the fair value of Cellectar Biosciences Inc stockQuarterly Portfolio Summary & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Bleichroeder group discloses 4.61% CLRB stake in amended ownership filing - Stock Titan
Is Cellectar Biosciences Inc. stock risky to hold now2025 Top Gainers & Advanced Swing Trade Entry Alerts - mfd.ru
Cellectar Biosciences Inc (CLRB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):